CLINICAL TRIALS PROFILE FOR PEGAPTANIB SODIUM
✉ Email this page to a colleague
All Clinical Trials for pegaptanib sodium
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00040313 ↗ | Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula | Completed | Eyetech Pharmaceuticals | Phase 2 | 2002-10-01 | The purpose of the study is to determine whether pegaptanib sodium (Macugen) is safe and effective in slowing the leakage of fluid within the retina and thereby stabilizing or improving vision when compared to placebo injections. A total of 176 patients will be enrolled |
| NCT00087763 ↗ | Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD) | Completed | Pfizer | Phase 2 | 2004-03-01 | The purpose of this study is to determine if Macugen™ reduces foveal thickness and improves vision in patients with wet AMD. |
| NCT00087763 ↗ | Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD) | Completed | Eyetech Pharmaceuticals | Phase 2 | 2004-03-01 | The purpose of this study is to determine if Macugen™ reduces foveal thickness and improves vision in patients with wet AMD. |
| NCT00088192 ↗ | Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD) | Completed | Pfizer | N/A | 2004-07-01 | To provide Pegaptanib sodium injection to patients with subfoveal choroidal neovascularization (CNV) secondary to AMD, who are unable to participate in any of the Sponsor's other clinical studies with this drug for AMD, until such time as the patient's lesion is considered to have resolved or stabilized in the opinion of the treating ophthalmologist, or product becomes commercially available. |
| NCT00088192 ↗ | Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD) | Completed | Eyetech Pharmaceuticals | N/A | 2004-07-01 | To provide Pegaptanib sodium injection to patients with subfoveal choroidal neovascularization (CNV) secondary to AMD, who are unable to participate in any of the Sponsor's other clinical studies with this drug for AMD, until such time as the patient's lesion is considered to have resolved or stabilized in the opinion of the treating ophthalmologist, or product becomes commercially available. |
| NCT00088283 ↗ | Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) | Completed | Pfizer | Phase 2 | 2004-05-01 | Eyetech Pharmaceuticals Inc. and Pfizer, Inc. are studying an investigational drug, MacugenTM, for the possible treatment of CRVO. An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA). This investigational drug may slow the growth of abnormal blood vessels in the eye and may reduce tissue swelling in the eye. The purpose of this study is to compare the safety and efficacy of a Macugen™ injection to a "pretend" injection. In addition, the purpose of this study is to measure the action of the study drug in the body over a period of time and to check for the presence of the study drug in your blood (called pharmacokinetics or PK). This study will involve approximately 90 people. People who decide to participate will have an equal chance (1 in 3) to receive one of three study injections, two of which are Macugen™ and one of which is a "pretend" injection. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for pegaptanib sodium
Condition Name
Clinical Trial Locations for pegaptanib sodium
Trials by Country
Clinical Trial Progress for pegaptanib sodium
Clinical Trial Phase
Clinical Trial Sponsors for pegaptanib sodium
Sponsor Name
